Aptinyx Stock (NASDAQ:APTX)
Previous Close
$NaN
52W Range
$0.06 - $0.06
50D Avg
-
200D Avg
-
Market Cap
-
Avg Vol (3M)
$132.92K
Beta
1.22
Div Yield
-
APTX Company Profile
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
APTX Performance
Peer Comparison
Ticker | Company |
---|---|
NUVB | Nuvation Bio Inc. |
MGTA | Dianthus Therapeutics, Inc. |
ACHL | Achilles Therapeutics plc |
ADIL | Adial Pharmaceuticals, Inc. |
RVPH | Reviva Pharmaceuticals Holdings, Inc. |
ABVC | ABVC BioPharma, Inc. |
ADTX | Aditxt, Inc. |
CTMX | CytomX Therapeutics, Inc. |
SPRO | Spero Therapeutics, Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
RNAZ | TransCode Therapeutics, Inc. |
HILS | Tharimmune, Inc. |
EVLO | Evelo Biosciences, Inc. |
VRAX | Virax Biolabs Group Limited |
ASMB | Assembly Biosciences, Inc. |
ALLR | Allarity Therapeutics, Inc. |
NRBO | NeuroBo Pharmaceuticals, Inc. |
ATXI | Avenue Therapeutics, Inc. |
NLTX | Neurogene Inc. |
TIL | Instil Bio, Inc. |
ALRN | Aileron Therapeutics, Inc. |